Search

Your search keyword '"Urruticoechea-Arana, A."' showing total 285 results
Start Over Author "Urruticoechea-Arana, A."
285 results on '"Urruticoechea-Arana, A."'

2. Effectiveness of janus kinase inhibitors in relapsing giant cell arteritis in real-world clinical practice and review of the literature

Author

Loricera, Javier, Tofade, Toluwalase, Prieto-Peña, Diana, Romero-Yuste, Susana, de Miguel, Eugenio, Riveros-Frutos, Anne, Ferraz-Amaro, Iván, Labrador, Eztizen, Maiz, Olga, Becerra, Elena, Narváez, Javier, Galíndez-Agirregoikoa, Eva, González-Fernández, Ismael, Urruticoechea-Arana, Ana, Ramos-Calvo, Ángel, López-Gutiérrez, Fernando, Castañeda, Santos, Unizony, Sebastian, and Blanco, Ricardo

Published
2024
Full Text
View/download PDF

3. Ultrasound in the Evaluation of Dactylitis and Enthesitis in Psoriatic Arthritis

Author

Ana Urruticoechea-Arana, Mireia Moreno, Manuel Pujol, and Teresa Clavaguera

Subjects
Immunologic diseases. Allergy, RC581-607
Abstract

Dactylitis is a clinical concept that corresponds to the swelling of the whole finger or toe giving a sausage appearance. Although it can be observed in different diseases, it is a distinctive clinical feature of psoriatic arthritis and is associated with a poor prognosis. Ultrasound has made it possible to improve our understanding of the pathogenesis of psoriatic arthritis dactylitis, identifying associated structural alterations, namely, flexor tenosynovitis, subcutaneous tissue edema, pulley inflammation with thickening and intra-pulley Doppler signals, extensor paratenonitis, synovitis, pericapsular bone formation, and flexor enthesitis. Given its complexity, a consensus has yet to be reached on an ultrasound-based definition of dactylitis. In addition, enthesitis is one of the characteristic features of spondyloartritis. Enthesitis, like dactylitis, is among the clinical manifestations in the Assessment of SpondyloArthritis international Society classification criteria for both axial and peripheral spondyloartritis and is a key feature for classifying psoriatic arthritis with the Classification criteria for Psoriatic Arthritis criteria. Ultrasonography is a very useful tool for exploring the enthesis. We have a good sonographic definition, although ultrasound findings do not always allow us to differentiate between mechanical or inflammatory lesions. Elementary lesions that characterize enthesopathy are hypoechogenicity at the enthesis, thickened enthesis, calcification/enthesophyte at enthesis, erosion at enthesis, and Doppler signal at enthesis. Different composite indices have been proposed in order to classify spond yloarthropathies. This article reviews the evaluation of dactylitis and enthesitis from the sonographic perspective.

Published
2024
Full Text
View/download PDF

4. Subcutaneous vs intravenous abatacept in rheumatoid arthritis-interstitial lung disease. National multicentre study of 397 patients

Author

López-Maraver, Marta, Serrano-Combarro, Ana, Atienza-Mateo, Belén, del Val, Natividad, Casafont-Solé, Ivette, Melero-Gonzalez, Rafael B., Pérez-Linaza, Alba, Calvo Gutiérrez, Jerusalem, Mena-Vázquez, Natalia, Vegas-Revenga, Nuria, Domínguez-Casas, Lucía, Loarce Martos, Jesús, Peralta Ginés, Cilia Amparo, Diez Morrondo, Carolina, Pérez Albaladejo, Lorena, López Sánchez, Rubén, Manzano Canabal, Mª Guadalupe, Brandy-García, Anahy Mª, López Viejo, Patricia, Bonilla, Gema, Maiz-Alonso, Olga, Carrasco-Cubero, Carmen, Garijo Bufort, Marta, Moreno, Mireia, Urruticoechea-Arana, Ana, Ordóñez-Palau, Sergio, González-Montagut, Carmen, Giner Serret, Emilio, De Dios Jiménez De Aberasturi, Juan Ramón, Lozano Morillo, Fernando, Vázquez Rodríguez, Tomás, Carreira, Patricia E, Blanco Madrigal, Juan María, Miguel Ibáñez, Belén, Rodríguez López, Marina, Fernández-Díaz, Carlos, Loricera, Javier, Ferraz-Amaro, Iván, Ferrer-Pargada, Diego, Castañeda, Santos, and Blanco, Ricardo

Published
2024
Full Text
View/download PDF

5. Real-world apremilast use in biologic-naïve psoriatic arthritis patients. Data from Spanish clinical practice

Author

Gratacós-Masmitja, Jordi, Beltrán Catalán, Emma, Álvarez Vega, José Luis, Urruticoechea-Arana, Ana, Fito, Concepción, Maceiras, Francisco, Belzunegui Otano, Joaquín María, Fernández Melón, Julia, Chamizo Carmona, Eugenio, Abad Hernández, Miguel Ángel, Ros Vilamajó, Inmaculada, Castro Oreiro, Sonia, Pascual Alfonso, Eva, and Torre Alonso, Juan Carlos

Published
2024
Full Text
View/download PDF

7. Effectiveness and safety of tocilizumab in monotherapy in biologic-naïve and non-naïve patients with rheumatoid arthritis in a real-world setting

Author

Marsal Barril, Sara, Martin-Martinez, Mª Auxiliadora, Blanco-Garcia, Francisco Javier, Fernández-Nebro, Antonio, García de Vicuña, Rosario, Tornero-Molina, Jesús, Sánchez-Alonso, Fernando, Novella-Navarro, Marta, Escudero-Contreras, Alejandro, Alegre-Sancho, Juan José, Urruticoechea-Arana, Ana, Bustabad-Reyes, Maria Sagrario, Trenor-Larraz, Pilar, Pérez-Sandoval, Trinidad, Tevar-Sánchez, Maria Isabel, Sánchez-Costa, Jesús T., and Raya-Álvarez, Enrique

Published
2022
Full Text
View/download PDF

8. Certolizumab pegol effectiveness, survival and safety in patients with psoriasis: A multicenter retrospective analysis in daily clinical practice by the Spanish Psoriasis Group.

Author

Sahuquillo‐Torralba, Antonio, Mansilla‐Polo, Miguel, Pujol‐Marco, Conrad, Llamas‐Velasco, Mar, Rull, Eva V., Ruiz Villaverde, Ricardo, Ferran, Marta, Pitarch, Gerard, Lopez, Anna, Beltran, Emma, Urruticoechea‐Arana, Ana, Riera‐Monroig, Josep, Alsina, Merce, Vidal, David, Belinchón Romero, Isabel, Notario, Jaime, Carrascosa, José M., Gonzalez‐Delgado, Víctor, Mollet, Jordi, and Ribera, Miquel

Subjects
CERTOLIZUMAB pegol, PSORIATIC arthritis, DRUG efficacy, PATIENT safety, SURVIVAL rate
Abstract

Background: Certolizumab is an Fc‐free PEGylated tumor necrosis factor‐alpha (TNFα) inhibitor recently approved for the treatment of moderate‐to‐severe plaque psoriasis, although there is limited real‐world evidence on the effectiveness and safety in patients with plaque psoriasis treated with certolizumab. The objective of this article is to determine the effectiveness, drug survival, and safety, including pregnancy, childbirth, and lactation, of certolizumab in moderate‐to‐severe plaque psoriasis under real‐world conditions. Methods: This is a retrospective, multicenter, observational study performed in 15 hospitals in Spain. It evaluates the effectiveness and safety of certolizumab in plaque psoriasis in the clinical practice setting. Results: A total of 67 patients (73% female) were evaluated with a mean baseline Psoriasis Area Severity Index (PASI) of 8.9. At Week 12, the mean PASI was 2.3 (n = 67), 1.3 (n = 57) at Week 24 and 1.3 at Week 52 (n = 34). Absolute PASI < 3 was achieved in 69, 86, and 92% of patients at Weeks 12, 24, and 52, respectively, as observed. For its part, using the under‐response imputation analysis, PASI < 3 at Weeks 12, 24, and 52 were achieved by 69, 73, and 49% of the patients, respectively. A total of 35 patients (52%) had concomitant psoriatic arthritis, and, in 24 of them, Disease Activity in Psoriatic Arthritis Score (DAPSA) was recorded at baseline, with a mean value of 17.9 which decreased to 8.2 at Week 12 (n = 22) and to 3.6 at Week 24 (n = 18). Certolizumab treatment was discontinued in 14 out of 67 patients (21%), due to lack/loss of cutaneous or articular effectiveness (n = 11) or patient decision (n = 2) or adverse event in only one patient who developed active tuberculosis. A lower baseline PASI [hazard ratio (HR): 1.12 (1.02–1.23); P = 0.023] and a more significant reduction in PASI at Week 12 [HR: 1.16 (1.07–1.27); P < 0.001] and Week 52 [HR: 1.47 (1.11–1.96); P = 0.007] was shown to be significantly related with better survival for the entire follow‐up period. Fourteen patients were treated during pregnancy and/or lactation without reporting adverse events in either the patient or the newborn. Conclusions: Certolizumab consistently showed high effectiveness and drug survival rates in this real‐life cohort. The safety demonstrated in clinical trials during pregnancy and lactation seems to be confirmed in clinical practice. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

9. AB1408 JANUS KINASE INHIBITORS IN REFRACTORY INFLAMMATORY OCULAR SURFACE PATHOLOGY. MULTICENTER STUDY AND LITERATURE REVIEW

Author

Sanchez-Bilbao, L., primary, Martín-Varillas, J. L., additional, Calvo-Río, V., additional, Esteban-Ortega, M. D. M., additional, Munoz-Fernández, S., additional, Álvarez-Vega, J. L., additional, Torre-Salaberri, I., additional, Urruticoechea-Arana, A., additional, Valls-Pascual, E., additional, Demetrio-Pablo, R., additional, and Blanco, R., additional

Published
2024
Full Text
View/download PDF

10. AB0694 BARICITINIB IN RHEUMATOID ARTHRITIS-INTERSTITIAL LUNG DISEASE. NATIONAL MULTICENTER STUDY OF 60 PATIENTS

Author

Serrano-Combarro, A., primary, Atienza-Mateo, B., additional, Valero Jaimes, J. A., additional, Pastor Mena, M., additional, Melero-González, R. B., additional, Castro-Corredor, D., additional, Martín López, M., additional, Castañeda, S., additional, Loarce-Martos, J., additional, Mena-Vázquez, N., additional, Carrasco Cubero, M. D. C., additional, Díez, C., additional, García-Valle, A., additional, Blanco-Madrigal, J. M., additional, Del-Val, N., additional, Vegas-Revenga, N., additional, Pérez Albaladejo, L., additional, Ortega-Castro, R., additional, Palma Sanchez, D., additional, Fernandez Ortiz, A. M., additional, López Viejo, P., additional, López Lasanta, M. A., additional, Garijo Bufort, M., additional, Casafont-Solé, I., additional, Moreno Morales, J., additional, Urruticoechea-Arana, A., additional, Pérez-García, C., additional, Rosas Gómez de Salazar, J., additional, Fernandez-Lozano, D., additional, Del Olmo Perez, L., additional, Lamúa Riazuelo, J. R., additional, Ferrer, D., additional, and Blanco, R., additional

Published
2024
Full Text
View/download PDF

11. POS0077 EFFECTIVENESS OF JANUS KINASE INHIBITORS IN RELAPSING GIANT CELL ARTERITIS IN REAL-WORLD CLINICAL PRACTICE AND REVIEW OF THE LITERATURE

Author

López-Gutiérrez, F., primary, Loricera, J., additional, Tofade, T., additional, Prieto-Peña, D., additional, Romero-Yuste, S., additional, De Miguel, E., additional, Labrador-Sánchez, E., additional, Riveros-Frutos, A., additional, Ferraz- Amaro, I., additional, Maiz, O., additional, Becerra-Fernández, E., additional, Narváez, J., additional, Galíndez-Agirregoikoa, E., additional, González, I., additional, Ramos Calvo, A., additional, Urruticoechea-Arana, A., additional, Castañeda, S., additional, Unizony, S., additional, and Blanco, R., additional

Published
2024
Full Text
View/download PDF

12. POS0689 WINDOW OF OPPORTUNITY IN THE TREATMENT OF RHEUMATOID ARTHRITIS-INTERSTITIAL LUNG DISEASE WITH ABATACEPT. NATIONAL MULTICENTER STUDY OF 526 PATIENTS

Author

Serrano-Combarro, A., primary, Atienza-Mateo, B., additional, Ibarrola Paino, L., additional, Casafont-Solé, I., additional, Loarce-Martos, J., additional, Blanco-Madrigal, J. M., additional, Castañeda, S., additional, Ortega-Castro, R., additional, Mena-Vázquez, N., additional, Vegas-Revenga, N., additional, Domínguez Casas, L., additional, Peralta-Ginés, C., additional, Retuerto-Guerrero, M., additional, Pérez Albaladejo, L., additional, López-Sánchez, R., additional, Mazano Canabal, M. G., additional, Brandy-Garcia, A., additional, López Viejo, P., additional, Bonilla, G., additional, Maiz, O., additional, Carrasco Cubero, M. D. C., additional, Garijo Bufort, M., additional, Urruticoechea-Arana, A., additional, Ordoñez, S., additional, González-Montagut Gómez, C., additional, García-Valle, A., additional, De Dios Jiménez de Aberásturi, J. R., additional, Martín López, M., additional, Vazquez Rodriguez, T., additional, Fernandez-Lozano, D., additional, Braña Abascal, I., additional, Melero-González, R. B., additional, Giner, E., additional, Ruiz, V., additional, Ventín-Rodríguez, C., additional, Rodriguez Lopez, M., additional, Andújar-Brazal, P., additional, Fernández-Melón, J., additional, López, L. M., additional, Lamúa Riazuelo, J. R., additional, Pàmies, A., additional, Fernández-Díaz, C., additional, Loricera, J., additional, Ferrer, D., additional, and Blanco, R., additional

Published
2024
Full Text
View/download PDF

13. Ultrasound in the Evaluation of Dactylitis and Enthesitis in Psoriatic Arthritis.

Author

Urruticoechea-Arana, Ana, Moreno, Mireia, Pujol, Manuel, and Clavaguera, Teresa

Subjects
PSORIATIC arthritis, SPONDYLOARTHROPATHIES, SYMPTOMS, BONE growth, SYNOVITIS, TENOSYNOVITIS
Abstract

Dactylitis is a clinical concept that corresponds to the swelling of the whole finger or toe giving a sausage appearance. Although it can be observed in different diseases, it is a distinctive clinical feature of psoriatic arthritis and is associated with a poor prognosis. Ultrasound has made it possible to improve our understanding of the pathogenesis of psoriatic arthritis dactylitis, identifying associated structural alterations, namely, flexor tenosynovitis, subcutaneous tissue edema, pulley inflammation with thickening and intra-pulley Doppler signals, extensor paratenonitis, synovitis, pericapsular bone formation, and flexor enthesitis. Given its complexity, a consensus has yet to be reached on an ultrasound-based definition of dactylitis. In addition, enthesitis is one of the characteristic features of spondyloartritis. Enthesitis, like dactylitis, is among the clinical manifestations in the Assessment of SpondyloArthritis international Society classification criteria for both axial and peripheral spondyloartritis and is a key feature for classifying psoriatic arthritis with the Classification criteria for Psoriatic Arthritis criteria. Ultrasonography is a very useful tool for exploring the enthesis. We have a good sonographic definition, although ultrasound findings do not always allow us to differentiate between mechanical or inflammatory lesions. Elementary lesions that characterize enthesopathy are hypoechogenicity at the enthesis, thickened enthesis, calci ficat ion/e nthes ophyt e at enthesis, erosion at enthesis, and Doppler signal at enthesis. Different composite indices have been proposed in order to classify spond yloar throp athie s. This article reviews the evaluation of dactylitis and enthesitis from the sonographic perspective. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

14. Development of an application for mobile phones (App) based on the collaboration between the Spanish Society of Rheumatology and Spanish Society of Family Medicine for the referral of systemic autoimmune diseases from primary care to rheumatology

Author

Urruticoechea-Arana, Ana, León-Vázquez, Fernando, Giner-Ruiz, Vicente, Andréu-Sánchez, José Luis, Olivé-Marqués, Alejandro, Freire-González, Mercedes, Pego-Reigosa, José María, Muñoz-Fernández, Santiago, Román-Ivorra, José A., Alegre-Sancho, Juan José, Vargas-Negrín, Francisco, Medina-Abellán, María, Cobo-Ibáñez, Tatiana, Mas-Garriga, Xavier, Calvo-Alén, Jaime, Costa-Ribas, Carmen, Blanco-Vela, Ricardo, Pérez-Martín, Álvaro, Beltrán-Catalán, Emma, Forcada-Gisbert, Jordi, Hernández-Miguel, María Victoria, Hermosa-Hernán, Juan Carlos, Narváez-García, Javier, Nieto-Pol, Enrique, and Rúa-Figueroa, Íñigo

Published
2020
Full Text
View/download PDF

15. Desarrollo de una aplicación para teléfonos móviles (app) basada en la colaboración Sociedad Española de Reumatología/Sociedad Española de Medicina de Familia y Comunitaria para derivación de enfermedades autoinmunes sistémicas

Author

Urruticoechea-Arana, Ana, León-Vázquez, Fernando, Giner-Ruiz, Vicente, Andréu-Sánchez, José Luis, Olivé-Marqués, Alejandro, Freire-González, Mercedes, Pego-Reigosa, José María, Muñoz-Fernández, Santiago, Román-Ivorra, José A., Alegre-Sancho, Juan José, Vargas-Negrín, Francisco, Medina-Abellán, María, Cobo-Ibáñez, Tatiana, Mas-Garriga, Xavier, Calvo-Alén, Jaime, Costa-Ribas, Carmen, Blanco-Vela, Ricardo, Pérez-Martín, Álvaro, Beltrán-Catalán, Emma, Forcada-Gisbert, Jordi, Hernández-Miguel, María Victoria, Hermosa-Hernán, Juan Carlos, Narváez-García, Javier, Nieto-Pol, Enrique, and Rúa-Figueroa, Íñigo

Published
2020
Full Text
View/download PDF

16. Current status of multidisciplinary care in psoriatic arthritis in Spain: NEXUS 2.0 project

Author

Queiro, Rubén, Coto, Pablo, Joven, Beatriz, Rivera, Raquel, Navío Marco, Teresa, de la Cueva, Pablo, Alvarez Vega, Jose Luis, Narváez Moreno, Basilio, Rodriguez Martínez, Fernando José, Pardo Sánchez, José, Feced Olmos, Carlos, Pujol, Conrad, Rodríguez, Jesús, Notario, Jaume, Pujol Busquets, Manel, García Font, Mercè, Galindez, Eva, Pérez Barrio, Silvia, Urruticoechea-Arana, Ana, Hergueta, Merce, López Montilla, M. Dolores, Vélez García-Nieto, Antonio, Maceiras, Francisco, Rodríguez Pazos, Laura, Rubio Romero, Esteban, Rodríguez Fernandez Freire, Lourdes, Luelmo, Jesús, and Gratacós, Jordi

Published
2020
Full Text
View/download PDF

17. Estado actual de la atención multidisciplinar para pacientes con artritis psoriásica en España: proyecto NEXUS 2.0

Author

Queiro, Rubén, Coto, Pablo, Joven, Beatriz, Rivera, Raquel, Navío Marco, Teresa, de la Cueva, Pablo, Alvarez Vega, Jose Luis, Narváez Moreno, Basilio, Rodriguez Martínez, Fernando José, Pardo Sánchez, José, Feced Olmos, Carlos, Pujol, Conrad, Rodríguez, Jesús, Notario, Jaume, Pujol Busquets, Manel, García Font, Mercè, Galindez, Eva, Pérez Barrio, Silvia, Urruticoechea-Arana, Ana, Hergueta, Merce, López Montilla, M. Dolores, Vélez García-Nieto, Antonio, Maceiras, Francisco, Rodríguez Pazos, Laura, Rubio Romero, Esteban, Rodríguez Fernandez Freire, Lourdes, Luelmo, Jesús, and Gratacós, Jordi

Published
2020
Full Text
View/download PDF

20. Spanish Registry of Recent-onset Psoriatic Arthritis (REAPSER study): Aims and methodology

Author

Queiro, Rubén, Laiz, Ana, Seoane-Mato, Daniel, Galindez Agirregoikoa, Eva, Montilla, Carlos, Park, Hye Sang, Bethencourt Baute, Juan José, Bustabad, Sagrario, Pinto Tasende, Jose A., Tejón, Patricia, Joven Ibáñez, Beatriz, Ramírez, Julio, Cuervo, Andrea, Cañete, Juan D., Trenor Larraz, Pilar, Ordás, Carmen, Alonso, Sara, García-Fernández, Edilia, Toniolo, Elide, Moreno Ramos, Manuel José, Beteta, María Dolores, Lojo Oliveira, Leticia, Navío Marco, Teresa, Cebrián, Laura, Barbazán, Ceferino, Maceiras, Francisco, Rodriguez-Moreno, Jesús, Steiner, Martina, Muñoz-Fernández, Santiago, Nóvoa Medina, Francisco Javier, León, Manuel, Rubio, Esteban, Medina Luezas, Julio, Sánchez-González, María Dolores, Arévalo, Marta, Gratacós, Jordi, Senabre, José Miguel, Rosas, José Carlos, Santos Soler, Gregorio, Nieto-González, Juan Carlos, González, Carlos, López Robles, Alejandra, Álvarez Castro, Carolina, Ruiz Montesino, María Dolores, Torrente-Segarra, Vicenç, Fernández-Carballido, Cristina, Martínez-Vidal, María Paz, Jovani, Vega, Urruticoechea-Arana, Ana, Cabello Fernández, Yolanda, Toledo, María Dolores, Almodóvar, Raquel, Belmonte-Serrano, Miguel Ángel, Notario Ferreira, Irene, and Raya Álvarez, Enrique

Published
2019
Full Text
View/download PDF

21. Registro Español de Artritis Psoriásica de Reciente Comienzo (estudio REAPSER). Objetivos y metodología

Author

Queiro, Rubén, Laiz, Ana, Seoane-Mato, Daniel, Galindez Agirregoikoa, Eva, Montilla, Carlos, Park, Hye Sang, Bethencourt Baute, Juan José, Bustabad, Sagrario, Pinto Tasende, Jose A., Tejón, Patricia, Joven Ibáñez, Beatriz, Ramírez, Julio, Cuervo, Andrea, Cañete, Juan D., Trenor Larraz, Pilar, Ordás, Carmen, Alonso, Sara, García-Fernández, Edilia, Toniolo, Elide, Moreno Ramos, Manuel José, Beteta, María Dolores, Lojo Oliveira, Leticia, Navío Marco, Teresa, Cebrián, Laura, Barbazán, Ceferino, Maceiras, Francisco, Rodriguez-Moreno, Jesús, Steiner, Martina, Muñoz-Fernández, Santiago, Nóvoa Medina, Francisco Javier, León, Manuel, Rubio, Esteban, Medina Luezas, Julio, Sánchez-González, María Dolores, Arévalo, Marta, Gratacós, Jordi, Senabre, José Miguel, Rosas, José Carlos, Santos Soler, Gregorio, Nieto-González, Juan Carlos, González, Carlos, López Robles, Alejandra, Álvarez Castro, Carolina, Ruiz Montesino, María Dolores, Torrente-Segarra, Vicenç, Fernández-Carballido, Cristina, Martínez-Vidal, María Paz, Jovani, Vega, Urruticoechea-Arana, Ana, Cabello Fernández, Yolanda, Toledo, María Dolores, Almodóvar, Raquel, Belmonte-Serrano, Miguel Ángel, Notario Ferreira, Irene, and Raya Álvarez, Enrique

Published
2019
Full Text
View/download PDF

24. Recommendations for the Management of Comorbidity in Patients With Axial Spondyloarthritis in Clinical Practice

Author

González, Carlos, Curbelo Rodríguez, Rafael, Torre-Alonso, Juan Carlos, Collantes, Eduardo, Castañeda, Santos, Hernández, M. Victoria, Urruticoechea-Arana, Ana, Nieto-González, Juan Carlos, García, Javier, Abad, Miguel Ángel, Ramírez, Julio, Suárez, Carmen, Dalmau, Regina, Martín-Arranz, Maria Dolores, León, Leticia, Hermosa, Juan Carlos, Obaya, Juan Carlos, Otón, Teresa, and Carmona, Loreto

Published
2018
Full Text
View/download PDF

25. Recomendaciones para el manejo de la comorbilidad en la práctica clínica en pacientes con espondiloartritis axial

Author

González, Carlos, Curbelo Rodríguez, Rafael, Torre-Alonso, Juan Carlos, Collantes, Eduardo, Castañeda, Santos, Hernández, M. Victoria, Urruticoechea-Arana, Ana, Nieto-González, Juan Carlos, García, Javier, Abad, Miguel Ángel, Ramírez, Julio, Suárez, Carmen, Dalmau, Regina, Martín-Arranz, Maria Dolores, León, Leticia, Hermosa, Juan Carlos, Obaya, Juan Carlos, Otón, Teresa, and Carmona, Loreto

Published
2018
Full Text
View/download PDF

27. Psoriatic arthritis screening: A systematic literature review and experts' recommendations.

Author

Ana Urruticoechea-Arana, Diego Benavent, Fernando León, Raquel Almodovar, Isabel Belinchón, Pablo de la Cueva, Cristina Fernández-Carballido, Estíbaliz Loza, Jordi Gratacós, and Cribado Working Group

Subjects
Medicine, Science
Abstract

ObjectiveTo analyze the performance of psoriatic arthritis (PsA) screening tools, examine their implementation in daily practice, and reach a consensus about the best screening tool for implementation in daily practice in different medical settings.MethodsA systematic literature review (SLR), structured telephone interviews to hospitals, and a multidisciplinary nominal group meeting were all conducted. The SLR employed sensitive search strategies using Medline, Embase, and the Cochrane Library up to January 2020. Two reviewers independently selected articles that reported data on PsA screening tools and that included sufficient data to at least calculate the sensitivity and specificity of those tools (e.g., questionnaires, algorithms, specific questions, and biomarkers). The hospital interviews collected data regarding the process of suspected PsA diagnosis and referral to rheumatology, the implementation of PsA screening tools, and barriers and facilitators to implementation of those tools. In the nominal group meeting, a multidisciplinary team of experts discussed all these data and subsequently recommended a screening tool for implementation.ResultsThe SLR included 41 moderate-quality studies that analyzed 14 PsA screening tools, most of which were questionnaire-based tools. All of these studies reported a moderate-good performance but presented different characteristics regarding the time to completion or the number and type of items or questions. The implementation of screening tools was low (30.5%). The experts ultimately recommended regular use of a PsA screening tool, preferably the PURE-4 questionnaire.ConclusionsThe implementation of PsA screening tools like the PURE-4 questionnaire in daily practice likely improves the prognosis of PsA patients.

Published
2021
Full Text
View/download PDF

28. Multidisciplinary Care Models for Patients With Psoriatic Arthritis

Author

Queiro, Rubén, Coto, Pablo, Rodríguez, Jesús, Notario, Jaume, Navío Marco, Teresa, de la Cueva, Pablo, Pujol Busquets, Manel, García Font, Mercè, Joven, Beatriz, Rivera, Raquel, Alvarez Vega, Jose Luis, Chaves Álvarez, Antonio Javier, Sánchez Parera, Ricardo, Ruiz Carrascosa, Jose Carlos, Rodríguez Martínez, Fernando José, Pardo Sánchez, José, Feced Olmos, Carlos, Pujol, Conrad, Galindez, Eva, Pérez Barrio, Silvia, Urruticoechea Arana, Ana, Hergueta, Mercedes, Luelmo, Jesús, and Gratacós, Jordi

Published
2017
Full Text
View/download PDF

29. Modelos de atención multidisciplinar en pacientes con artritis psoriásica en España

Author

Queiro, Rubén, Coto, Pablo, Rodríguez, Jesús, Notario, Jaume, Navío Marco, Teresa, de la Cueva, Pablo, Pujol Busquets, Manel, García Font, Mercè, Joven, Beatriz, Rivera, Raquel, Alvarez Vega, Jose Luis, Chaves Álvarez, Antonio Javier, Sánchez Parera, Ricardo, Ruiz Carrascosa, Jose Carlos, Rodríguez Martínez, Fernando José, Pardo Sánchez, José, Feced Olmos, Carlos, Pujol, Conrad, Galindez, Eva, Pérez Barrio, Silvia, Urruticoechea Arana, Ana, Hergueta, Mercedes, Luelmo, Jesús, and Gratacós, Jordi

Published
2017
Full Text
View/download PDF

31. The EJES-3D tool for personalized prescription of exercise in axial spondyloarthritis through multimedia animations: pilot study

Author

Flórez, Mariano Tomás, Almodóvar, Raquel, García Pérez, Fernando, Rodríguez Cambrón, Ana Belén, Carmona, Loreto, Pérez Manzanero, María Ángeles, Aboitiz Cantalapiedra, Juan, Urruticoechea-Arana, Ana, Rodríguez Lozano, Carlos J., Castro, Carmen, Fernández-Carballido, Cristina, de Miguel, Eugenio, Galíndez, Eva, Álvarez Vega, José Luis, Torre Alonso, Juan Carlos, Linares, Luis F., Moreno, Mireia, Navarro-Compán, Victoria, Juanola, Xavier, and Zarco, Pedro

Published
2018
Full Text
View/download PDF

32. Real-world apremilast use in biologic-naïve psoriatic arthritis patients. Data from Spanish clinical practice

Author

Gratacós-Masmitja, Jordi, primary, Beltrán Catalán, Emma, additional, Álvarez Vega, José Luis, additional, Urruticoechea-Arana, Ana, additional, Fito, Concepción, additional, Maceiras, Francisco, additional, Belzunegui Otano, Joaquín María, additional, Fernández Melón, Julia, additional, Chamizo Carmona, Eugenio, additional, Abad Hernández, Miguel Ángel, additional, Ros Vilamajó, Inmaculada, additional, Castro Oreiro, Sonia, additional, Pascual Alfonso, Eva, additional, and Torre Alonso, Juan Carlos, additional

Published
2023
Full Text
View/download PDF

34. POS0035 INFLUENCE OF INTERSTITIAL LUNG DISEASE DURATION ON THE TREATMENT OF RHEUMATOID ARTHRITIS-INTERSTITIAL LUNG DISEASE. NATIONAL MULTICENTER STUDY OF 392 PATIENTS WITH ABATACEPT

Author

Serrano-Combarro, A., primary, Atienza-Mateo, B., additional, Del-Val, N., additional, Ibarrola Paino, L., additional, Casafont-Solé, I., additional, Melero, R., additional, Pérez Linaza, A., additional, Serrano-García, I., additional, Castañeda, S., additional, Ortega Castro, R., additional, Calvo Gutierrez, J., additional, Mena-Vázquez, N., additional, Vegas-Revenga, N., additional, Domínguez Casas, L., additional, Delgado-Beltran, C., additional, Díez, C., additional, Pérez Sandoval, T., additional, Retuerto-Guerrero, M., additional, Pérez Albaladejo, L., additional, López-Sánchez, R., additional, Mazano, M. G., additional, Brandy-Garcia, A., additional, López Viejo, P., additional, Bonilla, G., additional, Maiz, O., additional, Carrasco Cubero, M. D. C., additional, Garijo Bufort, M., additional, Moreno, M., additional, Urruticoechea-Arana, A., additional, Ordoñez, S., additional, González-Montagut Gómez, C., additional, Peralta-Ginés, C., additional, Osorio, M. C., additional, Cañadillas, E., additional, De Dios Jiménez de Aberásturi, J. R., additional, Lozano Morillo, F., additional, Vazquez Rodriguez, T., additional, Carreira, P., additional, Blanco, J. M., additional, Fernández-Díaz, C., additional, Loricera, J., additional, Ferraz-Amaro, I., additional, Ferrer, D., additional, and Blanco, R., additional

Published
2023
Full Text
View/download PDF

35. POS0835 EFFECTIVENESS AND SAFETY OF JAK INHIBITORS IN RHEUMATOID ARTHRITIS-INTERSTITIAL LUNG DISEASE. NATIONAL MULTICENTER STUDY OF 57 PATIENTS

Author

Serrano-Combarro, A., primary, Atienza-Mateo, B., additional, Valero Jaimes, J. A., additional, Pastor Mena, M., additional, Melero, R., additional, Castro-Corredor, D., additional, Martin Lopez, M., additional, Castañeda, S., additional, Loarce-Martos, J., additional, Mena-Vázquez, N., additional, Carrasco Cubero, M. D. C., additional, Díez, C., additional, García-Valle, A., additional, Bonilla, G., additional, Blanco, J. M., additional, Del-Val, N., additional, Vegas-Revenga, N., additional, Pérez Albaladejo, L., additional, Ortega Castro, R., additional, Palma Sanchez, D., additional, Fernandez Ortiz, A. M., additional, López Viejo, P., additional, López Lasanta, M. A., additional, Garijo Bufort, M., additional, Casafont-Solé, I., additional, Maiz, O., additional, Moreno Morales, J., additional, Urruticoechea-Arana, A., additional, Pérez, C., additional, Rosas, J., additional, Ferrer, D., additional, and Blanco, R., additional

Published
2023
Full Text
View/download PDF

37. AB0416 SUBCUTANEUS VS INTRAVENOUS ABATACEPT IN RHEUMATOID ARTHRITIS-INTERSTITIAL LUNG DISEASE. NATIONAL MULTICENTER STUDY OF 392 PATIENTS

Author

Serrano-Combarro, A., primary, Atienza-Mateo, B., additional, Del-Val, N., additional, Ibarrola Paino, L., additional, Casafont-Solé, I., additional, Melero, R., additional, Pérez Linaza, A., additional, Serrano-García, I., additional, Castañeda, S., additional, Ortega Castro, R., additional, Calvo Gutierrez, J., additional, Mena-Vázquez, N., additional, Vegas-Revenga, N., additional, Domínguez Casas, L., additional, Delgado-Beltran, C., additional, Díez, C., additional, Pérez Sandoval, T., additional, Retuerto-Guerrero, M., additional, Pérez Albaladejo, L., additional, López-Sánchez, R., additional, Mazano, M. G., additional, Brandy-Garcia, A., additional, López Viejo, P., additional, Bonilla, G., additional, Maiz, O., additional, Carrasco Cubero, M. D. C., additional, Garijo Bufort, M., additional, Moreno, M., additional, Urruticoechea-Arana, A., additional, Ordoñez, S., additional, González-Montagut Gómez, C., additional, Peralta-Ginés, C., additional, De Dios Jiménez de Aberásturi, J. R., additional, Osorio, M. C., additional, Cañadillas, E., additional, Lozano Morillo, F., additional, Vazquez Rodriguez, T., additional, Carreira, P., additional, Blanco, J. M., additional, Fernández-Díaz, C., additional, Loricera, J., additional, Ferraz-Amaro, I., additional, Ferrer, D., additional, and Blanco, R., additional

Published
2023
Full Text
View/download PDF

38. AB0709 EFFECTIVENESS OF JANUS KINASE INHIBITORS IN GIANT CELL ARTERITIS IN CLINICAL PRACTICE. REAL-WORLD CLINICAL PRACTICE STUDY AND LITERATURE REVIEW

Author

Álvarez-Reguera, C., primary, Loricera, J., additional, Tofade, T., additional, Prieto-Peña, D., additional, Romero-Yuste, S., additional, De Miguel, E., additional, Riveros, A., additional, Ferraz-Amaro, I., additional, Castañeda, S., additional, Labrador-Sánchez, E., additional, Maiz, O., additional, Becerra-Fernández, E., additional, Narváez, J., additional, Galíndez-Agirregoikoa, E., additional, González Fernández, I., additional, Urruticoechea-Arana, A., additional, Unizony, S., additional, and Blanco, R., additional

Published
2023
Full Text
View/download PDF

39. OP0126 LONG-TERM FOLLOW UP OF ABATACEPT IN USUAL INTERSTITIAL PNEUMONIA ASSOCIATED TO RHEUMATOID ARTHRITIS. NATIONAL MULTICENTER STUDY OF 172 PATIENTS

Author

Atienza-Mateo, B., primary, Serrano-Combarro, A., additional, Del-Val, N., additional, Ibarrola Paino, L., additional, Casafont-Solé, I., additional, Melero, R., additional, Pérez-Linaza, A., additional, Serrano-García, I., additional, Castañeda, S., additional, Ortega Castro, R., additional, Calvo Gutierrez, J., additional, Mena-Vázquez, N., additional, Vegas-Revenga, N., additional, Domínguez-Casas, L. C., additional, Osorio, M. C., additional, Cañadillas, E., additional, Peralta-Ginés, C., additional, Delgado-Beltran, C., additional, Díez, C., additional, Pérez Sandoval, T., additional, Retuerto-Guerrero, M., additional, Pérez Albaladejo, L., additional, López-Sánchez, R., additional, Mazano, M. G., additional, Brandy-Garcia, A., additional, López Viejo, P., additional, Bonilla, G., additional, Maiz-Alonso, O., additional, Carrasco Cubero, M. D. C., additional, Garijo Bufort, M., additional, Moreno, M., additional, Urruticoechea-Arana, A., additional, Ordoñez, S., additional, González-Montagut Gómez, C., additional, De Dios Jiménez de Aberásturi, J. R., additional, Lozano Morillo, F., additional, Vazquez Rodriguez, T., additional, Carreira, P., additional, Blanco, J. M., additional, Fernández-Díaz, C., additional, Loricera, J., additional, Ferraz-Amaro, I., additional, Ferrer, D., additional, and Blanco, R., additional

Published
2023
Full Text
View/download PDF

40. AB1470 JANUS KINASE INHIBITORS IN SEVERE INFLAMMATORY OCULAR PATHOLOGY. MULTICENTER STUDY AND LITERATURE REVIEW

Author

Sanchez-Bilbao, L., primary, Martín-Varillas, J. L., additional, Calvo-Río, V., additional, Álvarez Vega, J. L., additional, Beltrán, E., additional, Esteban-Ortega, M. D. M., additional, Muñoz Fernandez, S., additional, Maiz, O., additional, Torre-Salaberri, I., additional, Urruticoechea-Arana, A., additional, Valls-Pascual, E., additional, Álvarez-Reguera, C., additional, Demetrio-Pablo, R., additional, and Blanco, R., additional

Published
2023
Full Text
View/download PDF

41. POS1142 SPANISH NATIONAL REGISTRY OF BELIMUMAB IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS

Author

Laino, M., primary, Enguita, M., additional, Castañeda, S., additional, Loricera, J., additional, Moriano, C., additional, Lasa, C., additional, Calvo-Río, V., additional, Narváez, J., additional, Navarro Palomo, P., additional, Casafont-Solé, I., additional, Font, J., additional, Gallego, A., additional, Carrión Barberà, I., additional, Quiroga Colino, P., additional, García-Aparicio, Á., additional, Belzunegui Otano, J. M., additional, López, M., additional, De Dios Jiménez de Aberásturi, J. R., additional, Hernández, S., additional, Heredia, S., additional, Fariña, A., additional, Navarro Blasco, F. J., additional, Ortega Castro, R., additional, DEL Olmo Perez, L., additional, Labrador-Sánchez, E., additional, Pinillos, V., additional, Ortega de la O, M. C., additional, Castro, P., additional, Blanco, J. M., additional, Paulino Huertas, M., additional, Matias de la Mano, M. A., additional, Peralta-Ginés, C., additional, Garcia-Cirera, S., additional, Camins, J., additional, Urruticoechea-Arana, A., additional, Medina Malone, M., additional, Cossio Jimenez, P. J., additional, Perez-Pampín, E., additional, Varas, B., additional, Vázquez, C., additional, Vegas-Revenga, N., additional, Rusinovich, O., additional, Giner, E., additional, Lamúa-Riazuelo, J. R., additional, and Aldasoro, V., additional

Published
2023
Full Text
View/download PDF

42. Audiovestibular Manifestations in Patients with Primary Raynaud’s Phenomenon and Raynaud’s Phenomenon Secondary to Systemic Sclerosis

Author

Amor-Dorado, Juan Carlos, primary, Martín-Sanz, Eduardo, additional, Franco-Gutiérrez, Virginia, additional, Urruticoechea-Arana, Ana, additional, García-Arumí, Ana M., additional, Racines-Álava, Erwin, additional, Alemán-López, Oscar, additional, Simeón-Aznar, Carmen P., additional, and González-Gay, Miguel Á., additional

Published
2023
Full Text
View/download PDF

43. Guselkumab effectiveness and survival in patients with psoriasis and psoriatic arthritis: Multicenter analysis in daily clinical practice by the Spanish Psoriasis Group

Author

Vicenç Rocamora, Laura Crespi, Marta Ferran, Mar Llamas‐Velasco, Elena del Alcázar, José M. Carrascosa, Emma Beltran, Ana Urruticoechea‐Arana, José Luis López Estebaranz, David Vidal, Josep Riera, Lourdes Rodríguez, Susana Armesto, Josep M. Fernández, Gloria Aparicio, Silvia Pérez, Saray Porcar, Encarna Montesinos, and Fernando Gallardo

Subjects
psoriatic arthritis, Adult, Male, Arthritis, Psoriatic, p19 inhibition, Dermatology, General Medicine, psoriasis, Middle Aged, Severity of Illness Index, guselkumab, Treatment Outcome, RWE, Humans, Psoriasis, Female, Retrospective Studies
Abstract

Guselkumab is a monoclonal antibody that selectively blocks the p19 subunit of interleukin 23 and has been approved for the treatment of moderate to severe psoriasis and active psoriatic arthritis in adult patients due to its efficacy in different clinical trials. Therefore, itis important to know the performance of guselkumab in this setting of patients in clinical practice given that a high percentage of them are not represented in these clinical trials. Our objective was to evaluate the effectiveness and tolerability of guselkumab in clinical practice in the first patients with psoriasis and psoriatic arthritis treated since the date of its approval for psoriasis in Spain, in joint dermatology-rheumatology clinics. A multicenter retrospective data collection was carried out, in which 14 hospitals participated, including a total of 90 patients with psoriatic arthritis confirmed by a rheumatologist. Data collection was recorded at baseline and at weeks 12, 24, and 52 for both the articular and cutaneous domains. Ninety PsA patients started treatment with guselkumab and therefore were included in this study. The vast majority had already failed to at least to one biologic therapyprior guselkumab prescription. The median age was 55 years, 61% were female and 46% had a BMI >= 30 kg/m(2). Sixty-nine percent suffered from peripheral arthritis, and in 34% an axial involvement was also detected; dactylitis or enthesitis was present in 24% and 29% of patients, respectively. Guselkumab was effective in controlling both articular and skin manifestations of PsA patients. Absolute PASI significantly decreased from 10.5 to 4.8, 1.9 and 1.3 at weeks 12, 24, and 52, respectively. In 29 out of 61 (48%) of cases, DAPSA was moderate or high, and patients showed a significant reduction in DAPSA at 12, 24, and 52 weeks of treatment (mean DAPSA values at baseline and follow up were 29, 20, 16, and 14, respectively). Patients with DAPSA in low activity or in remission at the time of initiation of guselkumab maintained response at the end of the study period. No new safety concerns were detected. Seventy-eight out of 90 patients (84.4%) persisted on treatment after 2 years follow-up. Our experience suggests that guselkumab isan effective drug for PsA and PsO patients in clinical practice with good tolerability and no additional safety signals, making it a new therapeutic alternative for the treatment of PsA and PsO patients.

Published
2022

44. Prevalence of Metabolic Syndrome in Psoriatic Arthritis

Author

Santos Castañeda, María A. Martín-Martínez, Miguel A. González-Gay, Ana Urruticoechea-Arana, D. Benavent, Teresa Otón, and Estíbaliz Loza

Subjects
Adult, Male, Metabolic Syndrome, medicine.medical_specialty, business.industry, Arthritis, Psoriatic, Middle Aged, medicine.disease, Dermatology, Cohort Studies, Psoriatic arthritis, Systematic review, Rheumatology, Cohort, Prevalence, medicine, Humans, Female, Metabolic syndrome, business
Abstract

To analyze the prevalence of metabolic syndrome (MetS) in patients with psoriatic arthritis (PsA) in a systematic literature review (SLR) and in the Spanish CArdiovascular in RheuMAtology (CARMA) cohort.A SLR and a subanalysis of the CARMA cohort were performed. In the SLR, PubMed, EMBASE, the Cochrane Library, and ClinicalTrials.gov up to March 2019 were searched. Systematic literature reviews, clinical trials, and observational studies that analyzed the prevalence or frequency of MetS in PsA were analyzed. Two reviewers selected the articles, assessed the quality of the studies, and collected data, independently. In addition, data on sociodemographic characteristics and MetS in patients with PsA from the CARMA cohort were collected and analyzed. Comparative descriptive analysis was performed.The SLR included 18 articles, of moderate to high quality, with PsA patients of both sexes, with mean ages between 42 and 59 years. The rate of MetS varied from 23.5% to 62.9%. The most commonly used classification method was that of the National Cholesterol Education Program. Additionally, 724 PsA patients from the CARMA cohort were analyzed; 327 (45.4%) were women, 157 (21.8%) smokers, with a mean age of 51 years and a mean PsA disease duration of 9 years. Hypertension was the most common abnormal finding (66.8%), followed by hyperglycemia (42.6%) and hypertriglyceridemia (30.6%). Notably, 222 patients (30.6%) had MetS.The prevalence of MetS in PsA varies, depending on the definition. Whereas 23.5% to 62.9% of PsA patients have MetS, in the CARMA cohort almost a third of patients with PsA have MetS.

Published
2021
Full Text
View/download PDF

45. Guselkumab effectiveness and survival in patients with psoriasis and psoriatic arthritis: Multicenter analysis in daily clinical practice by the Spanish Psoriasis Group

Author

Rocamora, Vicenç, primary, Crespi, Laura, additional, Ferran, Marta, additional, Llamas‐Velasco, Mar, additional, del Alcázar, Elena, additional, Carrascosa, José M., additional, Beltran, Emma, additional, Urruticoechea‐Arana, Ana, additional, Estebaranz, José Luis López, additional, Vidal, David, additional, Riera, Josep, additional, Rodríguez, Lourdes, additional, Armesto, Susana, additional, Fernández, Josep M., additional, Aparicio, Gloria, additional, Pérez, Silvia, additional, Porcar, Saray, additional, Montesinos, Encarna, additional, and Gallardo, Fernando, additional

Published
2022
Full Text
View/download PDF

47. Audiovestibular Manifestations in Patients with Primary Raynaud’s Phenomenon and Raynaud’s Phenomenon Secondary to Systemic Sclerosis

Author

Juan Carlos Amor-Dorado, Eduardo Martín-Sanz, Virginia Franco-Gutiérrez, Ana Urruticoechea-Arana, Ana M. García-Arumí, Erwin Racines-Álava, Oscar Alemán-López, Carmen P. Simeón-Aznar, and Miguel Á. González-Gay

Subjects
General Medicine, Raynaud phenomenon, audiovestibular, systemic sclerosis, balance disorder
Abstract

Objectives: To address the prevalence of audiovestibular disorders in patients with primary Raynaud’s Phenomenon (RP). A series of patients with primary RP and secondary RP in the context of systemic sclerosis (SSc) were compared with healthy controls. Methods: A prospective multicenter observational cross-sectional study was conducted in several Otolaryngology and Rheumatology Divisions of tertiary referral hospitals, recruiting 57 patients with RP and 57 age- and gender-matched controls. Twenty patients were classified as primary RP when unrelated to any other conditions and 37 patients who met the 2013 ACR/EULAR classification criteria for SSc were classified as having secondary RP associated with SSc. Audiometric and vestibular testing (vHIT), clinical sensory integration and balance testing (CTSIB), and Computerized Dynamic Posturography (CDP) were performed. Results: As significant differences were found in the age of the two study groups, primary and secondary RP, no comparisons were made between both groups of RP but only with their control groups. No sensorineural hearing loss (SNHL) was recorded in any of our patients with primary RP and no differences were found in the voice audiometry tests with respect to controls. Four of 37 (10.8%) secondary RP patients presented SNHL. Those with SNHL were 7.03 times more likely to have a secondary RP than controls (p < 0.001). The audiometric curve revealed high-frequency hearing loss in 4 patients with RP secondary to SSc, and statistically significant differences were achieved when RP secondary was compared to controls in vHIT gain, caloric test, CTSIB, and CDP. Conclusions: Unlike patients with RP secondary to SSc, patients with primary RP do not show audiovestibular abnormalities. Regarding audiovestibular manifestations, primary RP can be considered a different condition than secondary RP.

Published
2023
Full Text
View/download PDF

48. POS1350 UVEITIS DUE TO IMMUNE-MEDIATED INFLAMMATORY DISEASES TREATED WITH CERTOLIZUMAB PEGOL. MULTICENTER STUDY OF 80 PATIENTS.

Author

Martín-Varillas, J. L., primary, Sanchez-Bilbao, L., additional, Calvo-Río, V., additional, Adan, A., additional, Hernanz Rodriguez, I., additional, Beltrán, E., additional, Castro, S., additional, Fanlo Mateo, P., additional, García Martos, A., additional, Torre-Salaberri, I., additional, Cordero-Coma, M., additional, De Dios-Jiménez Aberásturi, J., additional, García-Aparicio, Á., additional, Hernández-Garfella, M., additional, Sanchez-Andrade, A., additional, García-Valle, A., additional, Miguélez, R., additional, Maiz, O., additional, Rodríguez Montero, S., additional, Urruticoechea-Arana, A., additional, Veroz Gonzalez, R., additional, Conesa, A., additional, Fernández-Carballido, C., additional, Jovani, V., additional, Martínez González, O., additional, Moya, P., additional, Romero-Yuste, S., additional, Rubio Muñoz, P., additional, Peña Sainz-Pardo, E., additional, Garijo Bufort, M., additional, Hernández, J. L., additional, and Blanco, R., additional

Published
2022
Full Text
View/download PDF

49. POS0828 BIOLOGIC THERAPY IN REFRACTORY PARENCHYMAL AND NON-PARENCHYMAL NEUROBEHÇET DISEASE: NATIONAL MULTICENTER STUDY

Author

Herrero-Morant, A., primary, Martín-Varillas, J. L., additional, Castañeda, S., additional, Maiz-Alonso, O., additional, Sanchez-Martin, J., additional, Ortego, N., additional, Raya, E., additional, Prior-Español, Á., additional, Moriano, C., additional, Melero, R., additional, Graña, J., additional, Urruticoechea-Arana, A., additional, Ramos Calvo, A., additional, Loredo Martínez, M., additional, Salgado-Pérez, E., additional, Sivera, F., additional, Torre-Salaberri, I., additional, Narváez, J., additional, Andréu Sánchez, J. L., additional, Martínez González, O., additional, Gómez de la Torre, R., additional, Fernández, S., additional, Romero-Yuste, S., additional, Gonzalez-Mazon, I., additional, Álvarez-Reguera, C., additional, Martínez-López, D., additional, Hernández, J. L., additional, González-Gay, M. Á., additional, and Blanco, R., additional

Published
2022
Full Text
View/download PDF

50. Biologic therapy in refractory neurobehcet's disease: a multicentre study of 41 patients and literature review

Author

Herrero-Morant, A, Martin-Varillas, JL, Castaneda, S, Maiz, O, Sanchez, J, Ortego, N, Raya, E, Prior-Espanol, A, Moriano, C, Melero-Gonzalez, RB, Grana-Gil, J, Urruticoechea-Arana, A, Ramos-Calvo, A, Loredo-Martinez, M, Salgado-Perez, E, Sivera, F, Torre, I, Narvaez, J, Andreu, JL, Martinez-Gonzalez, O, Gomez-de la Torre, R, Fernandez-Aguado, S, Romero-Yuste, S, Gonzalez-Mazon, I, Alvarez-Reguera, C, Hernandez, JL, Gonzalez-Gay, MA, and Blanco, R

Subjects
tocilizumab, rituximab, Neurobehcet, biologic therapy, anti-TNF, ustekinumab, canakinumab, anakinra
Abstract

Objectives To assess efficacy and safety of biologic therapy (BT) in neurobehcet's disease (NBD) refractory to glucocorticoids and at least one conventional immunosuppressive drug. Methods Open-label, national, multicentre study. NBD diagnosis was based on the International Consensus Recommendation criteria. Outcome variables were efficacy and safety. Main efficacy outcome was clinical remission. Other outcome variables analysed were glucocorticoid-sparing effect and improvement in laboratory parameters. Results We studied 41 patients [21 women; age 40.6 (10.8) years]. Neurological damage was parenchymal (n = 33, 80.5%) and non-parenchymal (n = 17, 41.5%). First BTs used were infliximab (n = 19), adalimumab (n = 14), golimumab (n = 3), tocilizumab (n = 3) and etanercept (n = 2). After 6 months of BT, neurological remission was complete (n = 23, 56.1%), partial (n = 15, 37.6%) and no response (n = 3, 7.3%). In addition, median (IQR) dose of oral prednisone decreased from 60 (30-60) mg/day at the initial visit to 5 (3.8-10) mg/day after 6 months (P < 0.001). It was also the case for mean erythrocyte sedimentation rate [31.5 (25.6)-15.3 (11.9) mm/1st h, P = 0.011] and median (IQR) C-reactive protein [1.4 (0.2-12.8) to 0.3 (0.1-3) mg/dl, P = 0.001]. After a mean follow-up of 57.5 months, partial or complete neurological remission persisted in 37 patients (90.2%). BT was switched in 22 cases (53.6%) due to inefficacy (n = 16) or adverse events (AEs) (n = 6) and discontinued due to complete prolonged remission (n = 3) or severe AE (n = 1). Serious AEs were observed in two patients under infliximab treatment. Conclusions BT appears to be effective and relatively safe in refractory NBD.

Published
2022

Catalog

Books, media, physical & digital resources
See catalog results